Abstract
This article serves as a formal correction to a 2021 study published in Theranostics (DOI: 10.7150/thno.49812). The authors address a clerical error in Figure 4A, where a post-injection fluorescence image was mistakenly duplicated as a pre-injection control. The corrected data reaffirms the efficacy of 5HFeC nanoparticles in targeting myeloperoxidase (MPO) for the high-sensitivity detection of vulnerable atherosclerotic plaques.
Introduction: Identifying High-Risk Atherosclerosis
Atherosclerosis is a leading cause of cardiovascular disease worldwide. However, the clinical risk of heart attack or stroke is primarily driven by "vulnerable" plaques—lesions characterized by intense inflammation and a thin fibrous cap that are prone to sudden rupture. Traditional clinical imaging often struggles to distinguish these high-risk lesions from stable, calcified plaques.
To bridge this gap, researchers have focused on myeloperoxidase (MPO), an enzyme secreted by activated macrophages and neutrophils. MPO serves as a critical biomarker for plaque instability and impending rupture, making it an ideal target for molecular imaging.
Methodology
The study utilized a multimodal imaging strategy to detect MPO activity in vivo:
- 5HFeC Nanoparticles: These specialized agents are designed to bind specifically to active MPO within the inflammatory environment of the plaque.
- Magnetic Particle Imaging (MPI): A cutting-edge modality that detects the magnetic signature of iron oxide nanoparticles. MPI offers exceptional sensitivity and contrast because it produces no background signal from biological tissues.
- Fluorescence Imaging (FLI): Employed as a complementary technique to visualize the spatial distribution of the nanoparticles.
The research was conducted using ApoE-/- mice, a genetically modified model that develops human-like atherosclerosis when fed a high-fat diet.
Corrected Results: Restoring the Baseline
The primary focus of this erratum is the correction of Figure 4A, which displays fluorescence imaging results. In the original publication, a clerical error led to the duplication of a 24-hour post-injection image as the "Pre" (baseline) control. The corrected figure restores the accurate baseline data, providing a clear comparison of nanoparticle accumulation.
As shown in the corrected figure:
- Baseline (Pre): The mouse exhibits negligible fluorescence signal in the thoracic and abdominal regions, confirming a clean baseline.
- 24 Hours Post-Injection: There is a significant increase in radiant efficiency, reaching levels above $10.0 \times 10^7 \frac{p/sec/cm^2/sr}{\mu W/cm^2}$. This signal is specifically localized to the area of the aorta where plaque develops.
Conclusion
The authors confirm that this clerical correction does not change the original results or the scientific conclusions of the paper. The 5HFeC nanoparticles effectively target and highlight active MPO in vivo, validating the potential of this platform for the sensitive detection of vulnerable atherosclerotic plaques. This work highlights the importance of rigorous baseline controls in molecular imaging and reinforces the promise of MPI in cardiovascular diagnostics.
Summary updated